Christopher A. Chapleau - Publications

Affiliations: 
University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
dendritic spines/ mental retardation

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Medeiros D, Ayala-Baylon K, Egido-Betancourt H, Miller E, Chapleau C, Robinson H, Phillips ML, Yang T, Longo FM, Li W, Pozzo-Miller L. A small-molecule TrkB ligand improves dendritic spine phenotypes and atypical behaviors in female Rett syndrome mice. Disease Models & Mechanisms. 17. PMID 38785269 DOI: 10.1242/dmm.050612  0.626
2023 Medeiros D, Ayala-Baylon K, Egido-Betancourt H, Miller E, Chapleau CA, Robinson HA, Phillips ML, Yang T, Longo F, Li W, Pozzo-Miller L. A small-molecule TrkB ligand improves dendritic spine phenotypes and atypical behaviors in female Rett syndrome mice. Biorxiv : the Preprint Server For Biology. PMID 37986936 DOI: 10.1101/2023.11.09.566435  0.647
2017 Ferreras S, Fernández G, Danelon V, Pisano MV, Masseroni L, Chapleau CA, Krapacher FA, Mlewski EC, Mascó DH, Arias C, Pozzo-Miller L, Paglini MG. Cdk5 Is Essential for Amphetamine to Increase Dendritic Spine Density in Hippocampal Pyramidal Neurons. Frontiers in Cellular Neuroscience. 11: 372. PMID 29225566 DOI: 10.3389/Fncel.2017.00372  0.727
2016 Arnold M, Cross R, Singleton KS, Zlatic S, Chapleau C, Mullin AP, Rolle I, Moore CC, Theibert A, Pozzo-Miller L, Faundez V, Larimore J. The Endosome Localized Arf-GAP AGAP1 Modulates Dendritic Spine Morphology Downstream of the Neurodevelopmental Disorder Factor Dysbindin. Frontiers in Cellular Neuroscience. 10: 218. PMID 27713690 DOI: 10.3389/Fncel.2016.00218  0.73
2013 Bello O, Blair K, Chapleau C, Larimore JL. Is memantine a potential therapeutic for Rett syndrome? Frontiers in Neuroscience. 7: 245. PMID 24381538 DOI: 10.3389/fnins.2013.00245  0.319
2013 Chapleau CA, Lane J, Larimore J, Li W, Pozzo-Miller L, Percy AK. Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options. Future Neurology. 8. PMID 24348096 DOI: 10.2217/Fnl.12.79  0.684
2013 Chapleau CA, Lane J, Pozzo-Miller L, Percy AK. Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. Current Clinical Pharmacology. 8: 358-69. PMID 24050745 DOI: 10.2174/15748847113086660069  0.638
2013 Larimore J, Ryder PV, Kim KY, Ambrose LA, Chapleau C, Calfa G, Gross C, Bassell GJ, Pozzo-Miller L, Smith Y, Talbot K, Park IH, Faundez V. MeCP2 regulates the synaptic expression of a Dysbindin-BLOC-1 network component in mouse brain and human induced pluripotent stem cell-derived neurons. Plos One. 8: e65069. PMID 23750231 DOI: 10.1371/Journal.Pone.0065069  0.765
2013 Pitcher MR, Ward CS, Arvide EM, Chapleau CA, Pozzo-Miller L, Hoeflich A, Sivaramakrishnan M, Saenger S, Metzger F, Neul JL. Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Human Molecular Genetics. 22: 2626-33. PMID 23462290 DOI: 10.1093/hmg/ddt111  0.627
2013 Arnold JJ, Hansen MS, Gorman GS, Inoue T, Rao V, Spellen S, Hunsinger RN, Chapleau CA, Pozzo-Miller L, Stamer WD, Challa P. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. Investigative Ophthalmology & Visual Science. 54: 1118-26. PMID 23307957 DOI: 10.1167/Iovs.12-10583  0.572
2012 Chapleau CA, Boggio EM, Calfa G, Percy AK, Giustetto M, Pozzo-Miller L. Hippocampal CA1 pyramidal neurons of Mecp2 mutant mice show a dendritic spine phenotype only in the presymptomatic stage. Neural Plasticity. 2012: 976164. PMID 22919518 DOI: 10.1155/2012/976164  0.79
2012 Chapleau CA, Pozzo-Miller L. Divergent roles of p75NTR and Trk receptors in BDNF's effects on dendritic spine density and morphology. Neural Plasticity. 2012: 578057. PMID 22548193 DOI: 10.1155/2012/578057  0.707
2012 Calfa G, Chapleau CA, Campbell S, Inoue T, Morse SJ, Lubin FD, Pozzo-Miller L. HDAC activity is required for BDNF to increase quantal neurotransmitter release and dendritic spine density in CA1 pyramidal neurons. Hippocampus. 22: 1493-500. PMID 22161912 DOI: 10.1002/Hipo.20990  0.767
2009 Chapleau CA, Larimore JL, Theibert A, Pozzo-Miller L. Modulation of dendritic spine development and plasticity by BDNF and vesicular trafficking: fundamental roles in neurodevelopmental disorders associated with mental retardation and autism. Journal of Neurodevelopmental Disorders. 1: 185-96. PMID 19966931 DOI: 10.1007/S11689-009-9027-6  0.728
2009 Chapleau CA, Calfa GD, Lane MC, Albertson AJ, Larimore JL, Kudo S, Armstrong DL, Percy AK, Pozzo-Miller L. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiology of Disease. 35: 219-33. PMID 19442733 DOI: 10.1016/J.Nbd.2009.05.001  0.788
2009 Larimore JL, Chapleau CA, Kudo S, Theibert A, Percy AK, Pozzo-Miller L. Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations. Neurobiology of Disease. 34: 199-211. PMID 19217433 DOI: 10.1016/J.Nbd.2008.12.011  0.739
2008 Chapleau CA, Carlo ME, Larimore JL, Pozzo-Miller L. The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media. Journal of Neuroscience Methods. 169: 182-90. PMID 18242714 DOI: 10.1016/j.jneumeth.2007.12.006  0.706
2007 Moore CD, Thacker EE, Larimore J, Gaston D, Underwood A, Kearns B, Patterson SI, Jackson T, Chapleau C, Pozzo-Miller L, Theibert A. The neuronal Arf GAP centaurin alpha1 modulates dendritic differentiation. Journal of Cell Science. 120: 2683-93. PMID 17635995 DOI: 10.1242/Jcs.006346  0.681
2007 Amaral MD, Chapleau CA, Pozzo-Miller L. Transient receptor potential channels as novel effectors of brain-derived neurotrophic factor signaling: potential implications for Rett syndrome. Pharmacology & Therapeutics. 113: 394-409. PMID 17118456 DOI: 10.1016/J.Pharmthera.2006.09.005  0.754
Show low-probability matches.